How should I manage a smoker with polycythemia (hemoglobin 18 g/dL) and atrial fibrillation?

Management of Smoker with Polycythemia (Hb 18 g/dL) and Atrial Fibrillation

This patient requires full-dose oral anticoagulation with a DOAC (preferred over warfarin), aggressive smoking cessation intervention, phlebotomy to maintain hematocrit <45%, and comprehensive cardiovascular risk factor management. 1

Immediate Priorities

1. Anticoagulation for Stroke Prevention

Start oral anticoagulation immediately - this is the cornerstone of AF management regardless of polycythemia status 1:

• Use a DOAC (apixaban, rivaroxaban, edoxaban, or dabigatran) as first-line rather than warfarin 1
• Calculate CHA2DS2-VASc score - if ≥2, anticoagulation is mandatory 1
• Use full standard doses unless specific dose-reduction criteria are met (renal impairment, age >80, low body weight) 1
• Do NOT reduce DOAC dose simply because of polycythemia or perceived bleeding risk 1

The 2024 ESC guidelines are explicit that DOACs are preferred over VKAs to prevent thromboembolism and intracranial hemorrhage 1. While polycythemia vera carries thrombotic risk 2, 3, case reports confirm that oral anticoagulation can be safely used in this population 2.

Critical caveat: Assess whether this is true polycythemia vera (JAK2-mutated myeloproliferative neoplasm) versus secondary polycythemia from smoking 4, 3. Smokers' polycythemia has lower thrombotic risk than polycythemia vera 3, but both still require anticoagulation for AF.

2. Distinguish Polycythemia Type

Determine if this is:

• Polycythemia vera: Check JAK2 mutation, bone marrow biopsy if indicated, splenomegaly, pruritus 5
• Secondary polycythemia from smoking: Elevated carboxyhemoglobin, COPD, decreased oxygen saturation 4, 3

This distinction matters for long-term hematologic management but does NOT change the immediate need for anticoagulation.

3. Phlebotomy Target

If polycythemia vera is confirmed, initiate phlebotomy with hematocrit target <45% 5:

• This is the backbone of PV treatment to prevent thrombosis
• Combined with aspirin 81 mg once or twice daily (unless contraindicated) 5
• Hb 18 g/dL corresponds to hematocrit ~54%, well above target

Important: The anticoagulation for AF takes precedence over aspirin monotherapy. If patient is on full anticoagulation, avoid adding antiplatelet therapy unless there's an acute vascular event 1. The 2024 ESC guidelines explicitly state that combining anticoagulants with antiplatelet agents should be avoided except for specific indications 1.

4. Aggressive Smoking Cessation

Smoking cessation is mandatory and has direct hematologic benefits 4:

• Recent 2025 data shows that 51% of polycythemic smokers successfully quit at 3 months with effective interventions 4
• Hemoglobin and hematocrit significantly decrease in those who quit smoking 4
• Recommend ≤3 standard drinks (≤30 grams) of alcohol per week as part of comprehensive risk factor management 1

Provide pharmacotherapy (varenicline, bupropion, or nicotine replacement) plus behavioral counseling.

Rate vs. Rhythm Control Strategy

Assess AF-related symptoms using validated tools 1:

For rate control (if minimally symptomatic):

• Beta-blockers as first-line (any ejection fraction) 1
• Alternative: diltiazem/verapamil if LVEF >40% 1
• Digoxin can be added if needed 1

For rhythm control (if symptomatic):

• Consider cardioversion or antiarrhythmic drugs 1
• If AF duration >24 hours, provide at least 3 weeks of anticoagulation before cardioversion 1
• Continue anticoagulation regardless of whether sinus rhythm is maintained 1

Comprehensive Risk Factor Management (ABC Pathway)

The 2024 ESC guidelines emphasize the ABC approach 1:

A - Avoid stroke with Anticoagulation (addressed above)

B - Better symptom management

• Rate or rhythm control based on symptoms 1

C - Cardiovascular and comorbidity management 1:

• Blood pressure control: Mandatory to reduce AF recurrence and cardiovascular events 1
• Weight loss: Target ≥10% reduction if overweight/obese to reduce AF burden 1
• Exercise program: Tailored regimen to improve cardiorespiratory fitness 1
• Screen for sleep apnea: Don't rely solely on questionnaires 1
• Diabetes management if present 1

Bleeding Risk Assessment

Assess and manage modifiable bleeding risk factors 1:

• Uncontrolled hypertension
• Labile INRs (not applicable if using DOAC)
• Medications (NSAIDs, antiplatelet agents)
• Alcohol excess (>8 drinks/week)

Do NOT use bleeding risk scores to withhold anticoagulation 1. The 2024 ESC guidelines explicitly state this is not recommended 1.

Monitoring and Follow-up

• Reassess thromboembolic risk periodically to ensure anticoagulation continues appropriately 1
• Monitor hematocrit if PV confirmed, maintain <45% 5
• Transthoracic echocardiogram to guide treatment decisions 1
• Track smoking cessation progress - expect hematologic improvement within 3 months if successful 4

Key Pitfalls to Avoid

1. Do NOT withhold anticoagulation due to polycythemia - the thrombotic risk from AF outweighs bleeding concerns 1, 2
2. Do NOT use antiplatelet therapy alone for stroke prevention in AF - it is explicitly not recommended 1
3. Do NOT combine aspirin with anticoagulation unless there's a specific acute indication (ACS, recent stent) 1
4. Do NOT underdose DOACs without meeting specific criteria 1
5. Do NOT stop anticoagulation even if rhythm control is successful 1